Padcev (enfortumab vedotin) is a groundbreaking treatment option for patients with advanced bladder cancer. Here are 10 key things you need to know about Padcev:
- Padcev is an antibody-drug conjugate that targets Nectin-4, a protein that is highly expressed in bladder cancer cells.
- The FDA approved Padcev in December 2019 for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have previously received platinum-containing chemotherapy and a PD-1/L1 inhibitor.
- Padcev is administered via intravenous infusion every three weeks and has shown significant efficacy in clinical trials, with response rates of up to 44% in patients who have failed other treatments.
- Common side effects of Padcev include fatigue, peripheral neuropathy, rash, and decreased appetite.
- Padcev is recommended for patients who have failed other standard treatments, including chemotherapy and immunotherapy.
- Padcev is not recommended for patients with severe liver or kidney problems, or those who are pregnant or breastfeeding.
- Padcev can cause serious side effects, including severe skin reactions, eye problems, and infusion-related reactions.
- Patients receiving Padcev will need to be closely monitored for side effects and may require dose adjustments or treatment interruptions.
- Padcev represents a new era in the treatment of advanced bladder cancer, offering hope to patients who have exhausted other options.
- Discuss with your doctor if Padcev may be a suitable treatment option for you or your loved one with advanced bladder cancer.